Have a personal or library account? Click to login
Comorbid overweight/obesity and chronic pancreatitis exacerbate the dyslipidemia progression in type 2 diabetic patients Cover

Comorbid overweight/obesity and chronic pancreatitis exacerbate the dyslipidemia progression in type 2 diabetic patients

Open Access
|Jul 2022

References

  1. American Diabetes Association. Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes-2018. Diabetes Care 41, 28–37, 2018.10.2337/dc18-S00329222374
  2. American Diabetes Association. Cardiovascular disease and risk management: standards of medical care in diabetes-2019. Diabetes Care 42, 103–123, 2019.10.2337/dc19-S01030559236
  3. Arora M, Koley S, Gupta S, Sandhu JS. A study on lipid profile and body fat in patients with diabetes mellitus. Anthropologist 9, 295–298, 2007.10.1080/09720073.2007.11891015
  4. Bilous II, Korda MM, Krynytska IY, Kamyshnyi AM. Nerve impulse transmission pathway-focused genes expression analysis in patients with primary hypothyroidism and autoimmune thyroiditis. Endocr Regul 54, 109–118, 2020a.10.2478/enr-2020-001332597152
  5. Bilous I, Pavlovych L, Krynytska I, Marushchak M, Kamyshnyi A. Apoptosis and cell cycle pathway-focused genes expression analysis in patients with different forms of thyroid pathology. OAMJMS 8, 784–792, 2020b.10.3889/oamjms.2020.4760
  6. Bluher M, Stumvoll M. Diabetes and Obesity. In: Bonora E., DeFronzo R (eds.). Diabetes Complications, Comorbidities and Related Disorders. Endocrinology. Springer Cham, 2020.10.1007/978-3-030-36694-0_1
  7. Chernatska O, Demikhov N, Rudenko T, et al. Assesment of the lipid profile correction in patients with arterial hypertension and type 2 diabetes mellitus. Azerbaijan Med J 1, 95–99, 2019.
  8. Chhatriwala MN, Patel MP, Patel DSB, Shah HN. Relationship between dyslipidemia and glycemic status in T type-2 Diabetes Mellitus. Nat J Lab Med 8, 1–4, 2019.10.7860/NJLM/2019/42887:2371
  9. Chitra R, Hinge, Sachin B. Ingle, Baban D. Adgaonkar. Body mass index, blood pressure and lipid profile in type 2 diabetes - review. Int J Cur Res Rev 10, 1–9, 2018.10.31782/IJCRR.2018.10101
  10. Christiansen E, Urban C, Merten N, Liebscher K, Karlsen KK, Hamacher A, Spinrath A, Bond AD, Drewke C, Ullrich S, Kassack MU, Kostenis E, Ulven T. Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA(1)/GPR40), a potential target for the treatment of type II diabetes. J Med Chem 51, 7061–7064, 2008.10.1021/jm801017818947221
  11. Conwell DL, Lee LS, Yadav D, Longnecker DS, Miller FH, Mortele KJ, Levy MJ, Kwon R, Lieb JG, Stevens T, Toskes PP, Gardner TB, Gelrud A, Wu BU, Forsmark CE, Vege SS. American pancreatic association practice guidelines in chronic pancreatitis: evidence-based report on diagnostic guidelines. Pancreas 43, 1143–1162, 2014.10.1097/MPA.0000000000000237543497825333398
  12. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Jüni P, Lettino M, Marx N, Mellbin LG, Ostgren CJ, Rocca B, Roffi M, Sattar N, Seferovic PM, Sousa-Uva M, Valensi P, Wheeler DC; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 41, 255–323, 2020.
  13. Degen AS, Krynytska IY, Kamyshnyi AM. Changes in the transcriptional activity of the entero-insular axis genes in streptozotocin-induced diabetes and after the administration of TNF-α non-selective blockers. Endocr Regul 54, 160–171, 2020.10.2478/enr-2020-001932857721
  14. Demikhova N, Cherkashyna L, Chernatska O. The relationship between lipid metabolism and albuminuria level with single nucleotide polymorphism -204a>c [rs 3808607] CYP7A1 gene in patients with 2 type diabetes mellitus and diabetic nephropathy. Rom J Diabetes Nutr Metab Dis 26, 253–261, 2019.10.2478/rjdnmd-2019-0026
  15. Gaman MA, Dobrica EC, Cozma MA, Antonie NI, Stanescu AMA, Gaman AM, Diaconu CC. Crosstalk of magnesium and serum lipids in dyslipidemia and associated disorders: a systematic review. Nutrients 13, 1411, 2021.10.3390/nu13051411814602333922341
  16. Gao D, Nong S, Huang X, Lu Y, Zhao H, Lin Y, Man Y, Wang S, Yang J, Li J. The effects of palmitate on hepatic insulin resistance are mediated by NADPH Oxidase 3-derived reactive oxygen species through JNK and p38MAPK pathways. J Biol Chem 285, 29965–29973, 2010.10.1074/jbc.M110.128694294326120647313
  17. Hamilton SJ, Watts GF. Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment. Rev Diabet Stud 10, 133–156, 2013.10.1900/RDS.2013.10.133406310024380089
  18. Hevko U, Kozak K, Krynytska I, Marushchak M. Diagnostic value of a complete blood count in type 2 diabetes mellitus and comorbidities. Arch Balk Med Union 55, 601–607, 2020.10.31688/ABMU.2020.55.4.06
  19. Hosseini S, Alipour M, Zakerkish M, Cheraghian B, Ghandil P. Effects of epigallocatechin gallate on total antioxidant capacity, biomarkers of systemic low-grade inflammation and metabolic risk factors in patients with type 2 diabetes mellitus: the role of FTO-rs9939609 polymorphism. Arch Med Sci 17, 1722–1729, 2020.10.5114/aoms.2020.95903864149134900054
  20. International Diabetes Federation. IDF Diabetes Atlas. 9th edition Brussels (BEL). IDF. 2019. https://www.diabetesatlas.org/en/
  21. Jialal I, Singh G. Management of diabetic dyslipidemia: An update. World J Diabet 10, 280–290, 2019.10.4239/wjd.v10.i5.280652275631139315
  22. Khrystych TM. Blood lipids in chronic pancreatitis combined with coronary heart disease: limitations of correction. Gastroenterology 3, 56–63, 2014.
  23. Kutoh E, Hayashi J, Kuto AN. Efficacy and safety of dulaglutide in patients with absolute insulin deficiency. Endocr Regul 53, 187–190, 2019.10.2478/enr-2019-001931517629
  24. Leon BM, Maddox TM. Diabetes and cardiovascular disease: epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabet 6, 1246–1258, 2015.10.4239/wjd.v6.i13.1246460017626468341
  25. Maev IV, Kucheryavyy YuA. Autoimmune pancreatitis: current state of the art. Therap Arch 2, 56–61, 2012.
  26. Marushchak M, Krynytska І, Klishch I, Gabor G, Antonyshyn I. The relationship between experimental alimentary obesity and hard tooth tissues mineralization. Jordan Med J 51, 25–33, 2017.10.12816/0039753
  27. Marushchak M, Maksiv K, Krynytska I, Stechyshyn I. Glutathione antioxidant system of lymphocytes in the blood of patients in a setting of concomitant chronic obstructive pulmonary disease and arterial hypertension. Polski Merkur Lek 47(281), 177–182, 2019.
  28. Marushchak M, Krynytska I. Insulin receptor substrate 1 gene and glucose metabolism characteristics in type 2 diabetes mellitus with comorbidities. Ethiop J Health Sci 31, 1001, 2021.
  29. Mooradian AD, Albert SG, Haas MJ. Low serum high-density lipoprotein cholesterol in obese subjects with normal serum triglycerides: the role of insulin resistance and inflammatory cytokines. Diabetes Obes Metab 9, 441–443, 2007.10.1111/j.1463-1326.2006.00636.x
  30. Nowakowska M, Zghebi SS, Ashcroft DM, Buchan I, Chew-Graham C, Holt T, Mallen C, Van Marwijk H, Peek N, Perera-Salazar R, Reeves D, Rutter MK, Weng SF, Qureshi N, Mamas MA, Kontopantelis E. The comorbidity burden of type 2 diabetes mellitus: patterns, clusters and predictions from a large English primary care cohort. BMC Med 17, 145, 2019.10.1186/s12916-019-1373-y
  31. Pavlyshyn H, Kozak K, Marushchak M. Association between night eating syndrome in overweight and obese children 10-17 years of age and dyslipidemia. Romanian Journal of Diabetes, Nutrition and Metabolic Diseases 28, 69–76, 2021.
  32. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL et al. European Guidelines on cardiovascular disease prevention in clinical practice. Kardiol Pol 74, 821–936, 2016.10.5603/KP.2016.0120
  33. Posokhova K, Stechyshyn I, Krynytska I, Marushchak M, Birchenko I, Klishch I. Comparative study of the effect of various forms of quercetin on experimental diabetes. Romanian Journal of Diabetes, Nutrition and Metabolic Diseases 25, 383–388, 2018.10.2478/rjdnmd-2018-0046
  34. Rhee EJ, Kim HC, Kim JH, Lee EY, Kim BJ, Kim EM, et al. Guidelines for the management of dyslipidemia. Korean J Intern Med 34, 723–771, 2019.10.3904/kjim.2019.188
  35. Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 375, 2267–2277, 2010.10.1016/S0140-6736(10)60408-4
  36. Sapkota LB, Thapa S. Pattern of dyslipidemia in type 2 diabetic patients attending Tertiary Care Centre of Nepal. EC Endocrinology and Metabolic Research 4, 15–22, 2019.
  37. Shankarprasad DS, Gundalli S, Mahantesh B, Kashinakunti SV, Sunitha P. Lipid profile in Diabetes Mellitus. Ind J Pathol Oncol 290–294, 2015.10.5958/2394-6792.2015.00030.7
  38. Shatynska O, Tokarskyy O, Lykhatskyi P, Yaremchuk O, Bandas I, Mashtalir A. Dietary supplementation with magnesium citrate may improve pancreatic metabolic indices in an alloxan-induced diabetes rat model. Potr. S. J. F. Sci 14, 836–846, 2020.10.5219/1375
  39. Shemesh E, Zafrir B. Hypertriglyceridemia-related pancreatitis in patients with type 2 diabetes: links and risks. Diabetes Metab Syndr Obes 12, 2041–2052, 2019.10.2147/DMSO.S188856678996931632114
  40. Shen GX. Lipid disorders in diabetes mellitus and current management. Curr Pharm Anal 3, 17–24, 2007.10.2174/157341207779802386
  41. Silitonga HA, Siahaan JM, Anto EJ. Correlation between obesity and lipid profile in type 2 diabetes mellitus patients at the Endocrine and Metabolic Polyclinic in General Hospital Pirngadi Medan. Maced J Med Sci 7, 1309–1313, 2019.10.3889/oamjms.2019.312651434631110575
  42. Sirchak ES, Opalenyk SM. Violation of lipid profile in patients with chronic pancreatitis. Clin Exp Med 1, 59–63, 2017.
  43. Sydorchuk L, Dzhuryak V, Sydorchuk A, Levytska S, Petrynych V, Knut R, Kshanovska A, Iftoda O, Tkachuk O, Kyfiak P, Popovich A, Khomko O, Sydorchuk R. The cytochrome 11B2 aldosterone synthase gene rs1799998 single nucleotide polymorphism determines elevated aldosterone, higher blood pressure, and reduced glomerular filtration, especially in diabetic female patients. Endocr Regul 54, 217–226, 2020.10.2478/enr-2020-002432857720
  44. Trovati M, Cavalot F. Optimization of hypolipidemic and antiplatelet treatment in the diabetic patients with renal disease. J Am Soc Nephrol 15, 12–20, 2004.10.1097/01.ASN.0000093238.09114.40
  45. Ugwuja E, Ogbonna N, Nwibo A, Onimawo I. Overweight and obesity, lipid profile and atherogenic indices among civil servants in Abakaliki, South Eastern Nigeria. Ann Med Health Sci Res 3, 13–18, 2013.10.4103/2141-9248.109462363421323634323
  46. Verges B. Pathophysiology of diabetic dyslipidaemia: Where are we? Diabetologia 58, 886–899, 2015.10.1007/s00125-015-3525-8439216425725623
  47. Young EE, Okafor CN, Okwara CC. Diabetes mellitus, associated comorbidities and complications - A review. Journal of Medicine and Medical Sciences 7, 47–55, 2016.
  48. Zeqollari A, Spahiu K, Vyshka G, Cakerri L. Lipid profile in diabetes mellitus type 2 patients in Albania and the correlation with BMI, hypertension, and hepatosteatosis. J Family Med Community Health 1, 1018, 2014.
  49. Zhang Y, Yang S, Zhang M, Wang Z, He X, Hou Y, Bai G. Glycyrrhetinic acid improves insulin-response pathway by regulating the balance between the Ras/MAPK and PI3K/Akt pathways. Nutrients 11, 604, 2019.10.3390/nu11030604647047330871060
  50. Zhuravleva LV, Shekhovtsova YA. Comorbidity of chronic pancreatitis and diabetes type 2: possible options of pharmacoteraphy. Practical Likar 5, 21–25, 2016.
DOI: https://doi.org/10.2478/enr-2022-0018 | Journal eISSN: 1336-0329 | Journal ISSN: 1210-0668
Language: English
Page range: 168 - 177
Published on: Jul 13, 2022
Published by: Slovak Academy of Sciences, Mathematical Institute
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year

© 2022 Mariya Marushchak, Kateryna Kozak, Inna Krynytska, published by Slovak Academy of Sciences, Mathematical Institute
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.